Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Business Overview: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in the U.S. and R&D Systems Europe Ltd. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (controls and calibrators) divisions. The Company also holds a significant investment in ChemoCentryx, Inc. (CCX).
Key Financial Metrics
| Metric | Q1 FY1999 (Ended 9/30/98) | Q1 FY1998 (Ended 9/30/97) |
|---|---|---|
| Net Sales | $21,335,192 | $15,537,143 |
| Gross Margin | $14,720,315 (69.0%) | $10,991,237 (70.7%) |
| Net Earnings | $3,524,844 | $3,262,382 |
| Diluted EPS | $0.17 | $0.17 |
| Cash from Operations | $5,747,205 | $5,303,124 |
| Cash & Equivalents (End of Period) | $10,625,749 | $9,065,649 |
| Total Assets | $113,941,280 | $72,918,881 (Prior Year End) |
| Debt/Liquidity | Unsecured line of credit: $750,000 (No borrowings) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 37% ($5.8 million) year-over-year, driven by the July 1, 1998 acquisition of Genzyme Corporation's research products business and increased sales of existing cytokine and antibody products.
- Acquisition Impact: The Genzyme acquisition resulted in a significant increase in intangible assets (Goodwill and Customer List) and a corresponding spike in amortization expense ($2.39 million vs. $42,471 in the prior year).
- Margin Compression: Gross margin percentage decreased slightly from 70.7% to 69.0%. This was attributed to lower gross profit levels on acquired Genzyme inventory and product mix changes in the Biotechnology and Hematology divisions.
- Cash Position: Cash and cash equivalents decreased significantly from $27.4 million at June 30, 1998, to $10.6 million at September 30, 1998, primarily due to the $24.76 million cash outlay for the Genzyme acquisition.
- Stock Repurchases: The Company repurchased 94,000 shares of common stock for $1.41 million during the quarter.
Guidance, Outlook, and Risks
- Capital Expenditures: Total planned capital additions for the remainder of fiscal 1999 are expected to be approximately $6 million, financed by available funds and operating cash flow.
- Investment Obligations: The Company is obligated to purchase up to an additional $2 million of preferred stock in ChemoCentryx, Inc. (CCX) over the next year upon the achievement of certain milestones.
- Year 2000 Compliance: The Company is reviewing systems for Year 2000 compliance, planning to complete upgrades by mid-1999. Costs are not expected to be material, though risks regarding supplier/customer compliance remain.
- Market Risks: The Company faces risks related to the conversion of Genzyme customers to Techne products, price competition in cytokine research products, and foreign currency fluctuations (though historically immaterial).
- Dividends: The Company has never paid cash dividends and has no plans to do so in fiscal 1999.
Investor Verification Checklist
- Acquisition Integration: Verify the success rate of converting Genzyme customers to Techne products and the realization of projected synergies.
- Amortization Impact: Monitor the ongoing impact of the $2.4 million quarterly amortization expense on future net earnings.
- ChemoCentryx Milestones: Track the progress of ChemoCentryx, Inc. to determine if the additional $2 million investment obligation will be triggered.
- Liquidity Management: Confirm that the reduced cash balance ($10.6 million) remains sufficient to fund the planned $6 million in capital expenditures and ongoing operations without drawing on the line of credit.
- Year 2000 Costs: Watch for any unexpected material costs associated with Year 2000 system upgrades or supply chain disruptions.